Back to results
US 2019/0167576 A1Published application
Use of high affinity monoclonal antibody product binders to increase the duration of action of therapeutic monoclonal antibody products in a biologic tissue
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorIra Hyman Schachar
Life of this patent
Estimating the term…
Abstract
An anchor molecule is provided that (1) binds monoclonal antibody products with high affinity and (2) is anchored in a biologic tissue of interest. Therapeutic antibodies can either be delivered to the biologic tissue before, during, or after the delivery of the anchor molecule. Because the present invention binds monoclonal antibody products and is anchored in a biologic tissue, the result is that monoclonal antibody products are also anchored in a biologic tissue.
Claims58
An anchor molecule, comprising two functional regions or moieties:
- (1) a region or moiety that binds a therapeutic antibody or fragment thereof with a dissociation constant (KD) less than 10−6 M, and (2) a region or moiety that anchors the molecule in a biologic tissue of interest;
- wherein the anchor molecule when delivered to the biologic tissue of interest in combination with a therapeutic monoclonal antibody acts to retain the therapeutic monoclonal antibody in the tissue, thereby increasing the duration of action of the therapeutic monoclonal antibody.
Dependencies are inferred from the claim text.